RECRUITING

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

Description

The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.

Study Overview

Study Details

Study overview

The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

Condition
Pre-Eclampsia
Intervention / Treatment

-

Contacts and Locations

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 45 Years

    Sexes Eligible for Study

    FEMALE

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    University of Pennsylvania,

    Enrique Schisterman, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

    Kurt Barnhart, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

    Study Record Dates

    2029-06